stockrow
Monday 9 November 2026
Export SION’s income statement to Excel — free account
Sionna Therapeutics, Inc.
SION- EPS
- −61.0%
- Free cash flow
- −22.4%
Quarter to June 2026, against a year earlier
3.28
0.00
0.00%
Follow SION
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 2 | — | |
| Gross margin, % | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
| EBT | — | — | — | — | — | — | — | (47) | (62) | (75) | (97) | +26.2% | ||||||
| EBT margin, % | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| Net income | — | — | — | — | — | — | — | (47) | (62) | (75) | (97) | +26.2% | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | n/m | |||||
| Earnings | — | — | — | — | — | — | — | (16.11) | (15.99) | (1.88) | (2.18) | (65.8%) | ||||||
| Cash flow | — | — | — | — | — | — | — | (14.90) | (13.68) | (1.66) | (1.68) | (66.6%) | ||||||
| Capex | — | — | — | — | — | — | — | (0.38) | (0.01) | (0.01) | 0.00 | (84.3%) | ||||||
| Free cash flow | — | — | — | — | — | — | — | (15.28) | (13.69) | (1.67) | (1.68) | (67.0%) | ||||||
| Book value | — | — | — | — | — | — | — | (39.17) | (42.42) | 7.68 | 5.89 | n/m | ||||||
| Shares, m | — | — | — | — | — | — | — | 3 | 4 | 40 | 44 | +269.1% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | 0 | — | |||||
| P/S | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| P/B | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | — | — | — | (44) | (53) | (66) | (76) | +23.2% | |||||
| Capex | — | — | — | — | — | — | — | (1) | 0 | 0 | 0 | (41.9%) | ||||||
| Free cash flow | — | — | — | — | — | — | — | (45) | (53) | (67) | (76) | +22.0% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | — | — | — | — | — | 31 | 141 | 230 | 205 | +171.5% | |||||
| Net debt | — | — | — | — | — | — | — | (39) | (148) | (236) | (211) | +147.5% | ||||||
| Shareholders’ equity | — | — | — | — | — | — | — | (115) | (164) | 307 | 266 | n/m | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | — | — | — | — | — | 0.00 | (51.90) | (29.42) | (30.66) | (29.4) pt | |||||
| ROIC | — | — | — | — | — | — | — | 0.00 | 0.00 | (78.38) | (125.00) | (78.4) pt | ||||||
| ROE | — | — | — | — | — | — | — | 0.00 | 44.29 | (105.18) | (32.34) | (105.2) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | — | — | — | 35 | 41 | 59 | — | +29.8% | |||||
| Revenue/emp, $m | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | — | n/m | ||||||
Negative figures in brackets.
estimates
Sionna Therapeutics, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| CNTN Canton Strategic Holdings, Inc. | $164.1M | — (loss-making) | — | — | n/m | −600.39% (below 0%: shrinking) | 100.00% | (80.37%) | Compare |
| IPHA Innate Pharma S.A. Sponsored ADR | $160.9M | — (loss-making) | — | +246.29% (above 0%: growing) | +106.08% (above 0%: growing) | −929.03% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| STRO Sutro Biopharma, Inc. | $159.5M | — (loss-making) | — (loss-making) | −84.57% (below 0%: shrinking) | n/m | +14.55% (above 0%: growing) | 100.00% | (303.77%) | Compare |
| ANTX AN2 Therapeutics, Inc. | $150.9M | — (loss-making) | — | — | n/m | +7.91% (above 0%: growing) | 0.00% | 0.00% | Compare |
| MGNX MacroGenics, Inc. | $148.4M | — (loss-making) | — (loss-making) | +47.62% (above 0%: growing) | n/m | +12.88% (above 0%: growing) | 100.00% | (42.19%) | Compare |
| SION Sionna Therapeutics, Inc. | $148.3M | — (loss-making) | — | — | n/m | −22.40% (below 0%: shrinking) | — | 0.00% | |
| NGEN NervGen Pharma Corp. | $143.1M | — (loss-making) | — | — | n/m | −48.10% (below 0%: shrinking) | — | 0.00% | Compare |
| VRXA Veraxa Biotech AG | $140.4M | — | — | — | — | — | — | — | Compare |
| INO Inovio Pharmaceuticals, Inc. | $125.6M | — (loss-making) | — (loss-making) | −83.19% (below 0%: shrinking) | n/m | +13.41% (above 0%: growing) | 100.00% | 0.00% | Compare |
| Median of peers | $149.7M | — | — | −17.78% | — | +7.91% | 100.00% | 0.00% |
Pay and ownership Proxy statement filed 27 April 2026
Ownership
Directors and executive officers, together
5.10%
Entities affiliated with RA Capital, L.P.
22.30%
Entities affiliated with TPG Growth
14.80%
Atlas Venture Fund XI, L.P
6.80%
OrbiMed Private Investments VIII, L.P.
6.60%
Entities affiliated with Viking Global Opportunities
6.50%
Sionna Aggregator, LP
5.50%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement